BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ke W, Li D, Tso LS, Wei R, Lan Y, Chen Z, Zhang X, Wang L, Liang C, Liao Y, Chen H, Liu Y, Zheng H, Yang L. Macrolide and fluoroquinolone associated mutations in Mycoplasma genitalium in a retrospective study of male and female patients seeking care at a STI Clinic in Guangzhou, China, 2016-2018. BMC Infect Dis 2020;20:950. [PMID: 33308173 DOI: 10.1186/s12879-020-05659-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Sweeney EL, Bradshaw CS, Murray GL, Whiley DM. Individualised treatment of Mycoplasma genitalium infection—incorporation of fluoroquinolone resistance testing into clinical care. The Lancet Infectious Diseases 2022. [DOI: 10.1016/s1473-3099(21)00629-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
2 Seo Y, Park H, Lee G. Molecular mechanisms of macrolide and fluoroquinolone resistance among Korean isolates of Mycoplasma genitalium over a period of five years 2014-2019. J Med Microbiol 2021;70. [PMID: 34812715 DOI: 10.1099/jmm.0.001460] [Reference Citation Analysis]
3 Fatoba AJ, Okpeku M, Adeleke MA. Subtractive Genomics Approach for Identification of Novel Therapeutic Drug Targets in Mycoplasma genitalium. Pathogens 2021;10:921. [PMID: 34451385 DOI: 10.3390/pathogens10080921] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
4 Shedko ED, Khayrullina GA, Goloveshkina EN, Akimkin VG. Clinical evaluation of commercial PCR assays for antimicrobal resistance in Mycoplasma genitalium and estimation of resistance-mediated mutation prevalence in Moscow and Moscow region. Eur J Clin Microbiol Infect Dis 2021;40:1413-8. [PMID: 33515097 DOI: 10.1007/s10096-021-04170-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]